Adavosertib (development codes AZD1775, MK-1775) is an experimental anti-cancer drug candidate. It is a small molecule inhibitor of the tyrosine kinase WEE1 with potential antineoplastic sensitizing activity. It is being developed by AstraZeneca.
It is being investigated as a treatment for pancreatic cancer with phase 1 trial. University of Michigan researchers are as of 2019 planning a phase 2 study.
Latest research - Adavosertib
Adavosertib is part of WikiMD's free ^articles!
^Adavosertib (article) is provided for informational purposes only. No expressed or implied warranties as to the validity of content.
Templates etc. when imported from Wikipedia, are licensed under CC BY-SA 3.0. See full disclaimers.